188Re DD-3b6/22 Fab' for use in therapy of ovarian cancer: Labelling and animal studies

Peter F. Schmidt, Suzanne V. Smith, Peter G. Bundesen

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


A fast and high yielding method of 188Re radiolabelling DD-3B6/22 Fab' is described. An inert atmosphere [N2(g)] and ascorbic acid was essential for preparation and storage of therapeutic levels (≤2 GBq/mg) for up to 24 h. Immunoreactivity was greater than 75%. Pharmacokinetic studies in nu/nu mice demonstrated localisation of 188SRe DD-3B6/22 Fab' was equivalent and correlated well with the behaviour observed for 99mTc DD- 3B6/22 Fab' used to image ovarian cancer. Excellent stability at the target site in vivo supports the potential use of 188Re DD-3B6/22 Fab' in the therapy of ovarian cancer.

Original languageEnglish
Pages (from-to)639-649
Number of pages11
JournalNuclear Medicine and Biology
Issue number7
Publication statusPublished or Issued - Oct 1998
Externally publishedYes


  • Antibody
  • Cancer
  • Immunotherapy
  • Radiolabelling
  • Re-188

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this